N/A
N=20
Investigating Two rTMS Strategies to Treat Cannabis Use Disorder
Cannabis Use Disorder
Bottom Line
View on ClinicalTrials.gov: NCT05720312 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Number (%) of Participants Who Started and Completed Treatment — 8; 8 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Repetitive Transcranial Magnetic Stimulation (rTMS) (Device)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Stanford University
- Primary completion
- May 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number (%) of Participants Who Started and Completed Treatment |
8; 8 | — |
| PRIMARY Number (%) of Participants Who Had Successful Generation of Functional Magnetic Resonance Imaging (fMRI) Targets |
10; 9 | — |
| PRIMARY Number (%) Weeks of Abstinence From Cannabis |
0; 56 | — |
| SECONDARY Number of Days of Use Per Week. |
6.82; 6.68; 5.27; 2.82 | — |
| SECONDARY Average Number of Use Sessions Per Week. |
50.33; 32.55; 29.68; 11.69 | — |
| SECONDARY Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Scale Score |
56.25; 54.82; 62.50; 67.63 | — |
| SECONDARY Number of Participants Who Had a Period of 4-consecutive Weeks of Abstinence During the Follow-up Period |
0; 4 | — |
Summary
In this trial we will work with a group of participants who are having problems related to marijuana use (they have Cannabis Use Disorder) and who want to reduce the amount of marijuana they use or quit using marijuana completely. We are testing to see if a treatment called repetitive transcranial magnetic stimulation (rTMS) can help them achieve that goal when combined with a brief three-session counseling therapy. Participants will receive rTMS to one of two different parts of the brain (the dorsolateral prefrontal cortex--the DLPFC or the ventromedial prefrontal cortex--the vmPFC) to see if applying rTMS to one brain area is more helpful than the other brain area.
Eligibility Criteria
Inclusion Criteria
- Participants must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.
- Participants must be between the ages of 18 and 60.
- Participants must meet DSM-5 criteria for at least moderate Cannabis Use Disorder, with use of at least 20 out of the last 28 days.
- Participants must express a desire to reduce cannabis use or quit.
- Participants must have a positive UDS for cannabis during their enrollment visit (confirming they are regular users).
- The investigative team must believe each participant is a good study-candidate.
Exclusion Criteria
- Participants must not be pregnant or breastfeeding.
- Participants must not meet moderate or severe use disorder of any other substance with the exception of tobacco/nicotine.
- Participants must not be on any medications that have central nervous system effects that have changed in the past 4-weeks.
- Participants must not have a history of/or current psychotic disorder or bipolar disorder.
- Participants must not have any other Axis I condition requiring current treatment.
- Participants must not have a history of Dementia or other cognitive impairment.
- Participants must not have active suicidal ideation, or a suicide attempt within the past 180 days.
- Participants must not have any contraindications to receiving rTMS or MRI (e.g. metal implanted above the head, history of seizure, any known brain lesion).
- Participants must not have any unstable general medical conditions.
Data sourced from ClinicalTrials.gov (NCT05720312). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.